Etripamil

Etripamil represents a significant advancement in the acute management of paroxysmal supraventricular tachycardia. As a short-acting, nondihydropyridine L-type calcium channel blocker, Etripamil exerts its anti-arrhythmic effect by inhibiting calcium influx through voltage-dependent L-type calcium channels (Cav1.2 and Cav1.3) expressed on atrioventricular nodal cells. Etripamil prolongs the refractory period and slows electrical conduction through the AV node, interrupting the re-entrant circuits responsible for AV-nodal dependent PSVT. Etripamil is formulated for intranasal administration, enabling rapid onset of action — clinical data shows significant efficacy in terminating arrhythmias within 15 to 60 minutes post-administration. Importantly, Etripamil has a short duration of action, with effects diminishing rapidly. The FDA approval of Etripamil nasal spray on December 12, 2025 marked the first commercially available product for acute PSVT conversion.

 

Product Parameters

---

Parameter	Specification
Product Name	Etripamil
CAS Number	1593673-23-4
Molecular Formula	C₂₇H₃₆N₂O₄
Molecular Weight	452.59 g/mol
Appearance	Brown to wine-red oily substance
Boiling Point	593.8±50.0℃
Density	1.079±0.06 g/cm3
Storage	Store at -20 °C

 

Why Cosperpharm?

---

When your cardiovascular research or PSVT drug development program requires high-purity Etripamil, Cosperpharm delivers with the quality, documentation, and supply flexibility that researchers and pharmaceutical developers demand.

 

Quality that supports critical research. Our Etripamil is released with comprehensive analytical characterization including HPLC purity verification (≥98%), NMR structural confirmation, and mass spectrometry identity verification. Every batch is accompanied by a Certificate of Analysis with full chromatographic traceability.

 

Documentation for your regulatory pathway. Each shipment includes a COA with batch-specific purity data, an SDS, and full customs documentation. For customers engaged in IND-enabling studies or regulatory submissions, Cosperpharm provides DMF-ready documentation packages upon request.

 

Flexible supply for all research scales. Cosperpharm supplies Etripamil from milligram quantities for screening and ion channel assays to gram-scale batches for preclinical studies and process development.

 

Technical expertise in calcium channel modulator chemistry. Our team understands the synthetic and analytical challenges of calcium channel blockers and can provide technical support for your Etripamil-related projects.

 

Global reach with transparent pricing. Cosperpharm ships to pharmaceutical companies, CROs, and research institutions worldwide. Volume discounts apply and we communicate lead times upfront.

 

Product Advantages

---

Rapid Onset of Action

Etripamil is designed for rapid onset of action via intranasal administration. Clinical data demonstrates significant efficacy in terminating PSVT episodes within 15 to 60 minutes post-administration, making it ideal for acute symptom management.

 

 Short Duration of Action

Unlike many calcium channel blockers with prolonged effects, Etripamil has a short duration of action. This favorable pharmacokinetic profile minimizes the risk of prolonged hypotension or bradycardia, an important safety advantage for acute use.

 

 Nondihydropyridine L-Type Calcium Channel Selectivity

Etripamil selectively targets L-type calcium channels (Cav1.2 and Cav1.3) expressed on AV nodal cells, arterial smooth muscles, and contractile myocardial cells. This selectivity underlies its specific anti-arrhythmic effects.

 

 Intranasal Formulation for Patient Convenience

Etripamil is formulated for intranasal administration, enabling self-administration by patients during acute PSVT episodes without the need for intravenous access or emergency department visits.

 

 Clinically Validated and FDA-Approved

Etripamil received FDA approval on December 12, 2025, as CARDAMYST™ nasal spray for the acute conversion of PSVT, confirming its efficacy and safety in a rigorous regulatory framework.

 

Product Quality Assurance

---

Cosperpharm has established a comprehensive quality assurance system for Etripamil that meets the rigorous expectations of pharmaceutical research and development:

 

Thorough analytical characterization. Each batch undergoes multi-technique analytical release testing: HPLC purity verification (≥98%), NMR structural confirmation, mass spectrometry identity verification, and appearance verification.

 

Full batch traceability. From raw material procurement through synthesis, purification, and final packaging, every step is fully documented and traceable. Each batch receives a unique lot number with retention samples maintained.

 

Stability monitoring. Cosperpharm conducts ongoing stability studies under recommended storage conditions. Etripamil pure form is stable for 3 years at -20°C and 2 years at 4°C.

 

Documentation ready for regulatory submission. Every shipment includes a COA with batch-specific purity and characterization data, an SDS, and customs documentation. For customers preparing regulatory submissions, DMF-ready documentation and custom quality agreements are available upon request.

 

Contact Us

---

Need Etripamil for your cardiovascular research, PSVT drug development, or calcium channel studies? Cosperpharm is ready to supply high-purity material with the documentation and support you need. Get in touch today — let's discuss how we can help advance your research.